138 related articles for article (PubMed ID: 33082322)
1. Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome.
Liu Y; Cai B; Chong Y; Zhang H; Kemp CA; Lu S; Chang CS; Ren M; Cowell JK; Hu T
Cell Death Dis; 2020 Oct; 11(10):884. PubMed ID: 33082322
[TBL] [Abstract][Full Text] [Related]
2. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
Cowell JK; Qin H; Hu T; Wu Q; Bhole A; Ren M
Int J Cancer; 2017 Nov; 141(9):1822-1829. PubMed ID: 28646488
[TBL] [Abstract][Full Text] [Related]
3. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
Zhang L; Wang H; Li W; Zhong J; Yu R; Huang X; Wang H; Tan Z; Wang J; Zhang Y
Oncotarget; 2017 Jan; 8(2):3289-3303. PubMed ID: 27924057
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment.
Cowell JK; Hu T
Cancer Drug Resist; 2021; 4(3):607-619. PubMed ID: 34734169
[TBL] [Abstract][Full Text] [Related]
6. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
[TBL] [Abstract][Full Text] [Related]
7. Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome.
Chong Y; Liu Y; Lu S; Cai B; Qin H; Chang CS; Ren M; Cowell JK; Hu T
Int J Cancer; 2020 Apr; 146(8):2243-2254. PubMed ID: 31525277
[TBL] [Abstract][Full Text] [Related]
8. miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the
Hu T; Chong Y; Lu S; Wang R; Qin H; Silva J; Kitamura E; Chang CS; Hawthorn L; Cowell JK
Cancer Res; 2018 Jul; 78(13):3522-3531. PubMed ID: 29735550
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.
Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A
Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937
[TBL] [Abstract][Full Text] [Related]
10. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
[TBL] [Abstract][Full Text] [Related]
11. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
12. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis.
Sun L; Huang Y; Liu Y; Zhao Y; He X; Zhang L; Wang F; Zhang Y
Cell Death Dis; 2018 Sep; 9(9):911. PubMed ID: 30185800
[TBL] [Abstract][Full Text] [Related]
13. An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.
Zimmermannova O; Doktorova E; Stuchly J; Kanderova V; Kuzilkova D; Strnad H; Starkova J; Alberich-Jorda M; Falkenburg JHF; Trka J; Petrak J; Zuna J; Zaliova M
Oncogene; 2017 Oct; 36(43):5985-5994. PubMed ID: 28650474
[TBL] [Abstract][Full Text] [Related]
14. FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
Hu T; Wu Q; Chong Y; Qin H; Poole CJ; van Riggelen J; Ren M; Cowell JK
Leukemia; 2018 Nov; 32(11):2363-2373. PubMed ID: 29720732
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK/p53/PUMA signals.
Song H; Wei M; Liu W; Shen S; Li J; Wang L
Histol Histopathol; 2018 Jan; 33(1):73-79. PubMed ID: 28287251
[TBL] [Abstract][Full Text] [Related]
16. DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis.
Hu T; Chong Y; Cai B; Liu Y; Lu S; Cowell JK
J Biol Chem; 2019 Nov; 294(48):18122-18130. PubMed ID: 31628193
[TBL] [Abstract][Full Text] [Related]
17. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Primary Drug Resistance in
Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
[No Abstract] [Full Text] [Related]
19. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
20. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.
Wu DW; Chen CY; Chu CL; Lee H
Oncogene; 2016 Feb; 35(5):621-30. PubMed ID: 25915848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]